Table 3 Regional cerebral blood flow before and after 12 weeks of clozapine treatment.
Patient sample (N = 24) | No covariates | Covarying for percent change of global CBF | ||||||
|---|---|---|---|---|---|---|---|---|
Baseline | Week 12 | Test statistics | Test statistics | |||||
F | df | P | F | df | P | |||
Global CBF, ml/100 g/min | 38.62 (10.48) | 36.26 (8.64) | 3.00 | 1 | 0.10 | / | / | / |
Regional CBF, ml/100 g/min | ||||||||
ACC | 37.12 (10.72) | 33.37 (8.35) | 8.66 | 1 | 0.01 | 11.18 | 1 | 0.00 |
Striatum | 40.43 (7.37) | 39.44 (7.49) | 0.76 | 1 | 0.39 | 0.07 | 1 | 0.80 |
Thalamus | 38.55 (8.68) | 36.87 (8.31) | 1.61 | 1 | 0.22 | 0.04 | 1 | 0.84 |
Hipp | 42.01 (8.01) | 41.34 (7.98) | 0.25 | 1 | 0.62 | 1.44 | 1 | 0.24 |
PANSS-Positive | 18.92 (5.98) | 14.33 (5.10) | 73.47 | 1 | <0.001 | / | / | / |
PANSS-Negative | 18.13 (6.42) | 15.29 (5.57) | 8.84 | 1 | 0.01 | / | / | / |
PANSS-General | 34.54 (7.44) | 27.04 (5.98) | 38.15 | 1 | <0.001 | / | / | / |
PANSS-Total | 71.58 (15.99) | 56.29 (14.11) | 58.54 | 1 | <0.001 | / | / | / |
GAF | 48.25 (9.31) | 59.42 (8.66) | 29.00 | 1 | <0.001 | / | / | / |
